Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities.

Autor: Vacca A; Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.; Clinica Medica, Department of Medicine, University of Udine, Udine, Italy., Wang R; Deutsches Herzzentrum Der Charité (DHZC), Charité-Universitätsmedizin Berlin, Berlin, Germany.; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.; Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany., Nambiar N; Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany., Capone F; Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.; Division of Internal Medicine, Department of Medicine-DIMED, University of Padua, Padua, Italy., Farrelly C; Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany., Mostafa A; Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany., Sechi LA; Clinica Medica, Department of Medicine, University of Udine, Udine, Italy., Schiattarella GG; Deutsches Herzzentrum Der Charité (DHZC), Charité-Universitätsmedizin Berlin, Berlin, Germany. gabriele.schiattarella@dhzc-charite.de.; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. gabriele.schiattarella@dhzc-charite.de.; Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. gabriele.schiattarella@dhzc-charite.de.; Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy. gabriele.schiattarella@dhzc-charite.de.
Jazyk: angličtina
Zdroj: Heart failure reviews [Heart Fail Rev] 2024 Sep 16. Date of Electronic Publication: 2024 Sep 16.
DOI: 10.1007/s10741-024-10439-1
Abstrakt: Heart failure with preserved ejection fraction (HFpEF) is rapidly growing as the most common form of heart failure. Among HFpEF phenotypes, the cardiometabolic/obese HFpEF - HFpEF driven by cardiometabolic alterations - emerges as one of the most prevalent forms of this syndrome and the one on which recent therapeutic success have been made. Indeed, pharmacological approaches with sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have proved to be effective due to metabolic protective effects. Similarly, lifestyle changes, including diet and exercise are crucial in HFpEF management. Increasing evidence supports the important role of diet and physical activity in the pathogenesis, prognosis, and potential reversal of HFpEF. Metabolic derangements and systemic inflammation are key features of HFpEF and represent the main targets of lifestyle interventions. However, the underlying mechanisms of the beneficial effects of these interventions in HFpEF are incompletely understood. Hence, there is an unmet need of tailored lifestyle intervention modalities for patients with HFpEF. Here we present the current available evidence on lifestyle interventions in HFpEF management and therapeutics, discussing their modalities and potential mechanisms.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: